Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT01893788

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Nagoya University (from the registry)
Registry
  • NCT NCT01893788
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01893788. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2016-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
Acronym
EARTH
Condition
Hypertensive Left Ventricular Hypertrophy
Intervention (Drug)
Aliskiren
Intervention (Drug)
Eplerenone
Lead sponsor
Nagoya University (class: other)

Record details

Record id
cardio:ct-nct01893788
Content hash
eaa952f60c1f90b3424233ae623dd4634588b124a562da93f7e03e584bf991a5